# Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin

> **NCT01434459** · PHASE1 · TERMINATED · sponsor: **Emory University** · enrollment: 9 (actual)

## Conditions studied

- Pancreatic Neoplasms
- Cholangiocarcinoma

## Interventions

- **DRUG:** Gemcitabine with TheraSphere

## Key facts

- **NCT ID:** NCT01434459
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-09
- **Primary completion:** 2014-01
- **Final completion:** 2014-09
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** PI moved to different institution
- **Last updated:** 2015-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01434459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01434459, "Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01434459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*